News
State bets $30 million on new cancer treatment
A new stem cell company that targets cancer by unleashing an “eat me” trigger has emerged from a $30 million investment by the state of California. Creation of the Palo Alto firm, which is called Forty Seven, Inc., was announced Feb. 24 by its backers and its key researcher, Irv Weissman, director of Stanford University’s stem cell program.